Erschienen in:
12.11.2018 | ASO Author Reflections
ASO Author Reflections: Use of Retrospective Administrative Datasets in Rare Cancer Subtypes to Determine the Efficacy of Adjuvant Therapy
verfasst von:
Ibrahim Nassour, MD, Adam C. Yopp, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
Perihilar cholangiocarcinoma is a rare disease posing a challenge for clinical researchers to conduct a well-designed trial studying the benefit of adjuvant therapy, whether chemotherapy or chemoradiation, in resected cases. All of the available studies on the subject are small, retrospective studies with conflicting results. The available randomized clinical trials have included a heterogeneous group of biliary malignancies, including gallbladder tumors, periampullary tumors, and intrahepatic, distal, and perihilar cholangiocarcinoma despite their different biology and susceptibility to systemic or radiation therapy. This has led to a lack of consensus on the optimal treatment for resected perihilar cholangiocarcinoma.
1–3 As such, using a large national database with a propensity score matching statistical technique allowed us to have a large sample size needed to elucidate the efficacy of adjuvant therapy on this rare malignancy and to determine the subset of patients who may benefit the most from chemotherapy or chemoradiation in the adjuvant setting.
4 …
